Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
针对接受新辅助治疗的可切除 III 期非小细胞肺癌 (NSCLC) 患者的性别特异性疗效和安全性结果:SAKK 试验 16/96、16/00、16/01、16/08 和 16/14 的汇总分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105870
Frehner, L; Schär, S; Hayoz, S; Guckenberger, M; Finazzi, T; Mark, M; Addeo, A; Mauti, L A; Betticher, D; Stupp, R; Curioni-Fontecedro, A; Peters, S; Früh, M; Rothschild, S I; Pless, M; König, D; Opitz, I; Ris, H B; Özdemir, B C; Schmid, S